docetaxel accord
accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w
doxorubicin mylan concentrate for soln for inf 2mg/ml (10ml vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin mylan concentrate for soln for inf 2mg/ml (25ml vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin mylan concentrate for soln for inf 2mg/ml (100ml vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin mylan pdr/conc/soln for infus 2mg/ml (10mg vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - powder for concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin mylan pdr/conc/soln for infus 2mg/ml (50mg vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - powder for concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin mylan concentrate for soln for inf 2mg/ml (5ml vial)
mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents
doxorubicin teva 2 mg/ml concentrate for solution for infusion
teva pharma b.v. - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin
doxorubicin 2 mg/ml concentrate for solution for infusion
accord healthcare ireland ltd. - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin
doxorubicin hydrochloride- doxorubicin hydrochloride injection, solution
fresenius kabi usa, llc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride injection, usp has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. patients should not be treated with doxorubicin if they have any of the following conditions: baseline neutrophil count <1,500 cells/mm 3 ; severe hepatic impairment; recent myocardial infarction; severe myocardial insufficiency; severe arrhythmias; previous treatment with complete cumulative doses of doxoru